Jiffar. T T; Yilmaz. T T; Lee. J J; Hanna. E E; El-Naggar. A A; Yu. D D; Myers. J N JN; Kupferman. M...
The study found that a protein called KiSS1 is often missing in head and neck cancers that are resistant to the chemotherapy drug cisplatin. When researchers turned KiSS1 back on, the cancer cells became more sensitive to the drug and were less likely to spread, improving survival in mouse models. This points to KiSS1 as a possible target for future cancer treatments, but it doesn’t offer any immediate actions for everyday health optimization.
Wiiger. Merete Thune MT; Bideli. Hemaseh H; Fodstad. Oystein O; Flatmark. Kjersti K; Andersson. Yvon...
Scientists tested a lab-made toxin (MOC31PE) that sticks to a protein on ovarian cancer cells and found it can kill those cells in a dish, especially when combined with the drug cyclosporin A. The study is purely pre‑clinical and does not provide any safe, usable method for people to improve health or longevity.
Vazquez-Alaniz. Fernando F; Galaviz-Hernandez. Carlos C; Marchat. Laurence A LA; Salas-Pacheco. Jos&...
The study looked at two genes, KiSS-1 and REN, in placentas from women with preeclampsia versus healthy pregnancies. It found that KiSS-1 levels were higher in preeclamptic placentas, while REN levels only rose in milder cases and were affected by how severe the disease was. The research is about pregnancy complications, not about using kisspeptin-10 for health or performance improvement.
Ziegler. Elke E; Olbrich. Teresa T; Emons. Günter G; Gründker. Carsten C
The study found that the peptide kisspeptin‑10 only slowed down cell growth when a special receptor (GPR54) was artificially added in large amounts, but it had no effect on normal breast cancer cells that naturally have the receptor. This suggests kisspeptin‑10 isn’t likely to be useful for health or anti‑cancer purposes in real life.
Torricelli. Michela M; Novembri. Romina R; Conti. Nathalie N; De Falco. Giulia G; De Bonis. Maria M;...
The study looked at how the hormone kisspein‑10 affects cell death in the placenta of pregnancies that go past the due date. It found that both kisspein‑10 and its receptor are higher in these placentas and that adding kisspein‑10 to placental tissue in the lab caused more cell death, especially at higher doses. The researchers think kisspein‑10 may naturally help trigger placental cell death in late or abnormal pregnancies.
Zhang. Hong H; Long. Qifang Q; Ling. Li L; Gao. Aihua A; Li. Huifen H; Lin. Qide Q
The study found that a protein called kisspeptin (KiSS-1) is higher in placentas from women with preeclampsia and that this higher level makes placental cells less able to invade, which may contribute to the disease.
Cebrian. Virginia V; Fierro. Marta M; Orenes-Piñero. Esteban E; Grau. Laura L; Moya. Patricia P...
The study looked at a gene called KISS1 in bladder cancer. It found that the gene is often turned off by a chemical change (methylation), which is linked to more advanced tumors and worse survival. Restoring the gene’s activity in lab cells required a drug that removes methyl groups.
Navenot. Jean-Marc JM; Evans. Barry B; Oishi. Shinya S; Setsuda. Shohei S; Fujii. Nobutaka N; Peiper...
A study tested a kisspeptin‑10‑based drug to stop melanoma spread in mice, but it didn’t help the animals live longer. The earlier positive results were likely due to a weird cell clone, not the drug itself. New experiments showed the drug doesn’t actually block cancer spread, so it isn’t useful for health‑boosting purposes.
Smith. Steven Christopher SC; Theodorescu. Dan D
The abstract talks about proteins that stop cancer from spreading and how scientists are trying to boost them with gene tricks or giving the proteins directly, but it doesn’t give any practical tips you can use for health, longevity, or performance.
Xie. Fei F; Yang. Houpu H; Wang. Shu S; Zhou. Bo B; Tong. Fuzhong F; Yang. Deqi D; Zhang. Jiaqing J
The study looked at early‑stage breast cancer patients and found that low levels of a protein called Kiss-1 (kisspeptin‑10) were linked to cancer spreading to the under‑arm lymph nodes. They built a statistical model that includes Kiss-1 and other tumor features to predict this spread, but the work is purely diagnostic and not about using the peptide for health improvement.
Avila. L L; Yuen. R K RK; Diego-Alvarez. D D; Peñaherrera. M S MS; Jiang. R R; Robinson. W P WP
The study looked at how gene activity and DNA tags change in different parts of a human placenta and found that the amount of KISS1 (kisspeptin) messenger RNA drops quickly after birth, while its DNA tags stay stable. This variability means you need several samples and fast processing to get accurate results, but it doesn’t give any direct tips for using kisspeptin‑10 in health or performance.
Heung. Macy M S MM; Jin. Shengnan S; Tsui. Nancy B Y NB; Ding. Chunming C; Leung. Tak Y TY; Lau. Tze...
This study looked at how well pieces of placental genetic material (including the KISS1 gene that makes kisspeptin) can be found in a pregnant woman's blood versus her plasma. It found that plasma is better for detecting fetal RNA, while most of the placental RNA found in whole blood actually comes from the mother, not the fetus. The research is about prenatal testing, not about using kisspeptin as a health supplement.
Shengbing. Zang Z; Feng. Liu Jing LJ; Bin. Wang W; Lingyun. Gao G; Aimin. Huang H
The study found that a gene called KiSS-1, which makes a peptide related to kisspeptin-10, is reduced in liver cancer tissue and even lower in tumors that have spread, and this drop is linked to higher cancer stage and more invasion. It also showed that when KiSS-1 is low, another protein that helps cells break down tissue, MMP-9, is higher.
Millar. Robert P RP; Roseweir. Antonia K AK; Tello. Javier A JA; Anderson. Richard A RA; George. Jyo...
The paper talks about chemicals that block kisspeptin, a hormone that controls the brain's release of reproductive signals. It shows that these blockers can help scientists study how puberty, menstrual cycles, and fertility work, but it doesn't give any tips for everyday health or performance.
Um. Haet Nim HN; Han. Ji Man JM; Hwang. Jong-Ik JI; Hong. Sung In SI; Vaudry. Hubert H; Seong. Jae Y...
The study maps how kisspeptin peptides and their GPR54 receptors have changed over evolution from fish to mammals, showing multiple gene copies and variations across species. It’s a basic science investigation of gene history, not a test of how kisspeptin-10 works in humans or how to use it for health.
Greives. Timothy J TJ; Long. Kimberly L KL; Burns. Christine M Bergeon CM; Demas. Gregory E GE
Most animals experience marked changes in reproductive status across development that are regulated by changes in the hypothalamo-pituitary-gonadal (HPG) axis. The upstream mechanisms regulating this axis remain less well understood. The neuropeptide kisspeptin serves as a positive regulator of reproduction; the precise actions of kisspeptin on the HPG axis in animals of differing developmental and seasonal reproductive states, however, remain unresolved. Further, sex differences in response to kisspeptin have not been fully explored. In Experiment 1, we investigated whether sensitivity to a broad range of kisspeptin doses differed in adult male and female Siberian hamsters held on reproductively inhibitory or stimulatory photoperiods. In Experiment 2, we asked whether the response to kisspeptin differed across stages of reproductive development. Males and females displayed elevated luteinizing hormone (LH) in response to kisspeptin; however, the sexes differed in this response, with males showing greater LH responses to kisspeptin than females. Hamsters responded to kisspeptin across all stages of reproductive development, although the magnitude of this response differed between animals of differental ages and between the sexes. Males showed significant increases in LH at an earlier developmental age than females; females also showed blunted LH responses during early adulthood whereas males remained relatively constant in their response to kisspeptin. These findings suggest that reproductively active and inactive hamsters are responsive to kisspeptin, but that the sexes differ in their responsiveness. Collectively, these data provide further insight into the basic actions of kisspeptin in the regulation of reproduction and provide a potential mechanism for the regulation of differential reproductive responses between the sexes.
Harris. L K LK; Jones. C J P CJ; Aplin. J D JD
The paper reviews how certain placenta cells stick together and move, describing the proteins they use, but it doesn’t give any tips or data that can be used for health, longevity, or performance improvements.
Greives. Timothy J TJ; Kriegsfeld. Lance J LJ; Demas. Gregory E GE
The study tested whether giving the hormone‑like peptide kisspeptin could stop or reverse the shrinking of reproductive organs that happens in hamsters when days get short. Across three experiments, giving kisspeptin didn’t change the outcome – hamsters still showed the same gonadal regression as untreated animals.
Torricelli. Michela M; Galleri. Letizia L; Voltolini. Chiara C; Biliotti. Giulia G; Florio. Pasquale...
The study looked at a hormone called kisspeptin made by the placenta and found that its gene activity goes up during labor, especially in early (pre‑term) births, but the amount of kisspeptin in the mother’s or baby’s blood doesn’t change, and adding kisspeptin to placenta tissue doesn’t affect oxytocin release.
Pang. Winnie W I WW; Tsui. Michelle H Y MH; Sahota. Daljit D; Leung. Tak Y TY; Lau. Tze K TK; Lo. Y...
The study looked at whether pieces of placental RNA floating in a pregnant woman's blood could tell us about the baby's growth. It found that one RNA (GH2) linked to birth weight, another (ADAM12) rose in a specific complication, but the kisspeptin (KISS1) RNA didn’t show useful differences. This information is mainly about pregnancy, not about adult health or performance.